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ABSTRACT 
CHARACTERIZATION OF REGULATORY MECHANISMS FOR  
ALTERNATIVE SPLICING IN ALPHA THYROID 
 HORMONE RECEPTOR mRNA 
 
 
Chao Zhang, B.S 
 
Marquette University, 2010 
 
 
In eukaryotes, alternative splicing is an essential post transcriptional modification process 
for functional gene expression and a major contributor to protein diversity.  The 
regulation of alternative splicing generally involves the engagements of RNA sequences 
cis-acting elements) and corresponding protein factors (trans-acting factors). The cis- 
acting RNA motifs can be categorized depending on positional and functional differences. 
Trans-acting protein factors will then bind to RNA sequences and affect the 
corresponding splicing activity. Recently, factors associated with 3’ polyadenylation have 
also been identified to affect alternative splicing.  
 
In mammals, the α-thyroid hormone receptor gene (TRα) produces transcripts for two 
functionally antagonistic isoforms, TRα1 and TRα2 by alternative splicing of pre-mRNA. 
TRα1 will activate the thyroid hormone responsive genes after the binding of thyroid 
hormone while TRα2, a non-hormone binding variant, plays a functionally antagonistic 
role. A third minor isoform, TRα3 has also been described which is similar to TRα2 but 
lacks part of the terminal sequence. Regulation of TRα alternative splicing requires the 
interaction of cis-trans elements and alternative polyadenylation. The goal of my project 
is to study the regulatory mechanism of TRα alternative splicing. 
 
In our system, ESX10 (exonic splicing enhancer on exon10) was previously identified as 
a 200 nt splicing enhancer element located on the last exon of TRα gene. My study 
further characterized the enhancing capability of exonic splicing enhancers (ESE) motifs 
within ESX10. Three heptanucleotide ESE motifs in the 3’ half of ESX10 have been 
identified. In vitro experiments indicate that substitution of eight nucleotides within three 
heptamers decreases the enhancing capability of ESX10. After substitution of ESX10 and 
its subfragments with Rev-erbβ sequence, cryptic splicing was detected and quantitated. 
Previous experiments also indicate that replacing original TRα1 and TRα2 poly (A) site 
with a strong SVL poly (A) signal would increase the corresponding mRNA expression. 
My results show that introduction of downstream poly (A) signal increases splicing 
fidelity. When upstream 5’ss of TRα2 is disabled, the strong poly (A) signal enhances the 
usage of weak splicing cites and promote cryptic splicing. 
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Chapter I. Introduction 
A. Background  
Alternative splicing in α-thyroid hormone (T3) receptor gene  
In higher eukaryotes, the expression of genes requires accurate and complete 
transcription to produce functional pre-mRNAs. This primary transcripts is typically 
modified by alternative splicing, a process in which spliced exons are connected after 
intron removal [1, 2].  Most variations produced by alternative splicing are from splicing 
at different splicing sites within mRNAs from a single gene, which normally leads to 
expression of different protein isoforms. Since its discovery about 30 years ago, 
alternative splicing has been addressed as an essential part of post transcriptional 
modification and a major contributor to protein diversity from the genome [3, 4]. It has 
been estimated that 95–100% of human genes with more than one exon undergo 
alternative processing, which may account for the existence of far fewer protein coding 
genes than originally predicted [5, 6, 7, 8].  Mistakes in alternative splicing are associated 
with autoimmune disease, neurodegenerative disorders and various cancers [7, 8]. 
       
In mammals, the α-thyroid hormone (T3) receptor gene (TRα, also known as NR1A1) 
produces transcripts for two functional antagonistic protein factors, TRα1 and TRα2 
through alternative splicing of TRα pre-mRNA [9,10,11,12]. The mature mRNAs for 
these two isoforms are identical except their 3' exons: TRα1 contains the complete 
sequence for the first 9 exons while the production of TRα2 requires specific splicing 
within exon 9 (at TRα2 specific 5' splice site) to exon 10 transcriptions (Figure 1). TRα1 
mRNA encodes the authentic thyroid hormone receptor that activates the downstream 
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thyroid hormone (T3) responsive genes after binding T3. In contrast, translation of TRα2 
produce a non-hormone binding variant that competes for the same DNA binding domain 
(T3 Response Elements) and will not involve in the following activation (Figure 1) 
[11,12]. TRα3, a further spliced isoform of TRα, has also been identified in rat from TRα 
alternative splicing. In TRα3, the proximal 39 amino acids sequence from exon10 of 
TRα2 has been deleted.  Functionally, TRα3 is similar to TRα2 in that TRα3 receptor 
doesn’t bind to thyroid hormone and won’t activate downstream genes [13, 14]. 
 
In addition to the TRα1 and TRα2 mRNAs, mRNA for another nuclear receptor protein, 
Rev-erbα is also transcribed from overlapping region but in the opposite direction [15, 
16]. Rev-erbα has been confirmed to play an important role in circadian regulation by 
controlling the transcription of BMAL1, one critical component of the molecular 
apparatus that regulates circadian rhythms [17, 18]. Rev-erbα was originally identified as 
an ‘orphan receptor’, which is a protein receptor that doesn’t have a known ligand. 
However, recent studies demonstrated that heme reversibly binds to Rev-erbα in its 
canonical ligand binding domain and regulate its interaction with other regulatory 
proteins [17, 18]. Since TRα and Rev-erbα share a 263 nt exon-exon overlap at their 3’ 
ends and their respective transcripts may interact with each other, the relationship 
between the sequence of these two physiological important genes has been studied by our 
laboratory. 
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TRβ and Rev-erbβ are two other nuclear receptor genes that are closely related to 
TRα and Rev-erbα. In Homo sapiens, TRα and Rev-erbα are located on chromosome 17 
while TRβ and Rev-erbβ genes are present on chromosome 3. Unlike TRα and Rev-erbα,  
TRβ and Rev-erbβ don’t share overlap sequence and are separated by approximately 150 
kb. Both TRα and TRβ encode for thyroid hormone receptors and mediate transcriptional 
activity in conjunction with numerous coactivators and corepressors [20, 21, 22]. Our 
study of TRα alternative splicing will provide insight for general alternative splicing 
mechanism and the possible regulatory rate of the antisense overlap. It may also 
contribute to understanding of the regulation of Rev-erbα. 
 
The identification and functional analysis of cis-acting elements in TRα alternative 
splicing 
In eukaryotes, the regulation of alternative splicing requires the participation of RNA 
sequence (cis-acting elements) and various protein factors (trans-acting factors), which 
promote or inhibit the assembly of the functional spliceosome. To achieve successful 
function of sequence motifs, different kinds of RNA-protein and protein-protein 
interactions are anticipated. [23, 24, 25]. According to their positional and functional 
difference, cis-acting RNA motifs can be categorized as: exonic splicing enhancer (ESE), 
exonic splicing silencer (ESS), intronic splicing enhancer (ISE) and intronic splicing 
silencer (ISS) [26, 27]. Trans-acting protein factor will then bind to these RNA sequences 
and affect the corresponding splicing activity. Typically, serine-arginine family protein 
factors (SR proteins) will bind to exonic splicing enhancers and positively affect the 
splicing efficiency. Many heterogeneous nuclear ribonucleoproteins (hnRNPs) are known 
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bind to ISS and ESS motifs and inhibit corresponding splicing activity. However, hnRNP 
F and hnRNP H could contribute to splicing enhancement after binding to certain intronic 
splicing enhancers [28, 29, 30]. Studies in our laboratory have been focused on the 
mechanism for regulating alternative splicing of TRα. The role of cis acting elements and 
polyadenylation on alternative splicing have been investigated in our system (Figure 2). 
 
Production of functional TRα2 mRNA requires cis-acting elements and corresponding 
tran-acting factors [31]. Previously, Dr. Michelle Hastings from our laboratory identified 
the specific enhancer SEα2, an 80 nt segment downstream of TRα2 5' splicing site [32]. 
SEα2 is a highly conserved sequence motif located in exon 9, which is also the final 
intron of TRα2. Substitution of the purine residues sequence inhibits the efficient splicing 
of TRα2 in vitro. Studies from a series of truncated constructs indicate that deletion of 
SEα2 induces a sharp decrease of normal TRα2 splicing in vivo [32].  The enhancing 
capability of SEα2 was also examined using heterologous pre-mRNAs. SEα2 segment 
was added to exon 4 in a truncated drosophila Dsx pre-mRNA [33, 34]. This change 
increased Dsx splicing efficiency more than threefold comparing to the negative control. 
SEα2's interaction with trans-acting factors was identified by in vitro competition 
experiments. If SEα2 binds to protein factors necessary for TRα2 splicing, an excess of 
SEα2 will inhibit TRα2 splicing competitively [32]. In competition experiments, different 
concentrations of wild-type and mutant competitor RNAs were incubated with TRα2 pre- 
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Figure 2. Regulatory mechanisms for TRα alternative splicing.
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Alternative of TRα involves different regulatory mechanisms. The interaction of cis acting elements and trans -
acting factors is one major category of regulation. The cis acting motifs RNA can be categorized into: exonic 
splicing enhancer (ESE), exonic splicing silencer (ESS), intronic splicing enhancer (ISE) and intronic splicing 
silencer (ISS). Splicing silencer elements are shown in red, splicing enhancer elements in green. Both ISS and 
ESS are hypothetical, while three different kinds of enhancing elements have been characterized. Selected 
examples of protein known to regulate splicing and polyadenylation are also included: U1 snRNP, U2AF65/35, 
SR protein, hnRNP proteins. Currently, we have identified  SEα2, TR-ISE3 and ESX10 as cis acting elements in 
our system. Interaction between SEα2 and SR protein factors has been identified[32]. Question mark indicate 
hypothetical regulation elements shown for illustrative purposes. 
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mRNA in HeLa nuclear extract for a fixed time period and corresponding TRα2 pre-
mRNA splicing efficiency was then evaluated. In contrast to mutant or non-specific RNA  
competitors, SEα2 derived competitors efficiently inhibit normal TRα2 splicing in vitro. 
Several tran-acting protein factors including SF2/ASF and hnRNPH were identified by 
protein–RNA crosslinking with radio-labeled SEα2 RNAs [32]. These experiments 
strongly suggested SEα2 and several associated protein factors are essential for 
production of TRα2 mRNA. Alternative splicing is often affected by specific sequence 
elements near the suboptimal 5’ or 3’ss [35]. TR-ISE3 (Thyroid Hormone Receptor-
intronic splicing enhancer-3’), a different type of cis-acting element was identified and 
studied by Ms. Valerie Salato in our lab [36, 37]. Multi-method studies with truncated 
constructs indicates that TR-ISE3 is a 90 nt sequence segment located upstream of 
3’splice site of TRα2 (Figure 2). In vitro splicing studies suggest that the whole length of 
TR-ISE3 is also essential for normal TRα2 production. Interestingly, SEα2 and TR-ISE3 
seem to have an additive effect on enhancing TRα2 splicing [36, 37], which suggests that 
they function independently. Such interaction between different cis-acting elements 
might be critical for alternative splicing.  
 
Another element important for splicing of TRα2 is ESX10 (exonic splicing enhancers on 
exon10), originally identified by Ms Salato. Because exon10 is the terminal exon for 
TRα2 and contains the overlapping region of two nuclear receptor proteins, the existence 
of cis-acting elements might contribute to the regulatory mechanism for transcription of 
both genes. Initially, a series of overlapping deletions were used to study the necessity of  
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Figure 3 Schematic structure of ESX10 and its subfragment
A. In order to further characterize ESX10, ESX10 segment (GR fragment) was 
subdivided equally and named G100 and R100 according to their nearby 
restriction sites. R100 was divided into 6 consecutive overlapping fragments and 
named R42αA- R42αF starting from the 3’ end. Bioinformatics work predict that 
three heptamer motifs of R100 might be short ESE targets.  
B. A truncated drosophila Dsx in vitro system was used to study the enhancing 
capability of specific sequence segments.  Without its original enhancer, the pre-
mRNA spliced poorly. G100, R100 and other interesting sequences were inserted 
to the 3’ end separately to test enhancing ability. A-F indicate six 42 nt fragments 
of R100, described above. 
R70 FD’
R42 F R28 D’
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ESX10 and successfully narrowed the size of enhancing fragment to 200 nt [36, 37]. It is 
located downstream of TRα2 3’ss and named the GR fragment according to the 
surrounding restriction sites (BsrGI and EcoRI). The enhancing capability of ESX10 has  
been tested both in vitro and in vivo. Since Rev-erbβ sequence is 63% identical to the 
Rev-erbα sequence but shows little enhancing capability in in vitro splicing test, it is used 
in its antisense orientation as a negative control for the study of ESX10. Introduction of 
ESX10 fragment into Dsx system induced a significant increase of Dsx exon splicing 
compared to corresponding Rev-erbβ sequence. To characterize better the function of 
ESX10 in vivo, new constructs have been made with the original ESX10 substituted by 
corresponding Rev-erbβ sequence. Following transfections of HEK293 cells, total RNA 
was assayed by realtime PCR.  Results indicate that TRα2’s splicing was inhibited in the 
absence of normal ESX10. To further characterize ESX10, the GR fragment was 
subdivided equally into two fragments, named G100 and R100 according to their 
adjacent restriction sites. When both G100 and R100 were inserted into Dsx for in vitro 
splicing test, the R100 showed better enhancing capability [36, 37].  To better 
characterize enhancing segments, R100 was divided into 6 consecutive overlapping 
fragments and named R42αA-R42αF starting from the 3’ end [36, 37]. Each fragment is 
42 nt long and overlapping 28nt with neighboring fragments and the enhancing capability 
of each piece was tested with Dsx in vitro system (Figure 3B).  All six fragments 
promoted the splicing activity of Dsx pre-mRNA and their enhancing level were similar, 
which also indicate the existence of multiple enhancing elements within R100.  In order 
to further characterize critical enhancing motifs, a series of R70 sequence were generated 
with all possible combination of R42αF (R42βF) and 28nt R42αD’ (R42βD’) and their 
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enhancing capabilities were evaluated in vitro by Dsx system. The fragments with TRα 
sequence antisense to Rev-erbα displayed higher activity compared to the antisense Rev-
erbβ (R70αFαD’ > R70αFβD ’> R70βFαD’ >> R70βFβD’) [36, 37].  This ordering 
reflects the fractional representation of TRα sequence in each construct. The results from 
this series of experiments suggested that the authentic TRα sequence is important for the 
enhancing capability of ESX10 subfragments and we are interested in further studying 
the enhancing elements within R100. 
 
Alternative polyadenylation of TRα 
In addition to splicing, alternative processing of TRα pre-mRNA also involves alternative 
sites for polyadenylation [39, 40]. Polyadenylation is an important post-transcriptional 
process for eukaryotic mRNAs and is involved in many processes including facilitating 
translation, protecting mRNA from degradation in cytoplasm and exporting the mRNA 
from the nucleus for translation.  The process of polyadenylation introduces many 
adenylate residues to the 3’ end of the transcript. In animals, a typical signal associated 
with polyadenylation is the hexanucleotide sequence AAUAAA located approximately 
10-25 nt upstream of the polyadenylation site [40, 41, 42].  Each of the two TRα mRNAs 
has a unique poly (A) site. Previous work by two students, Ms.Angela Schnell and Ms 
Elizabeth Mackiel, contribute greatly to further analysis of the effect of polyadenylation 
on TRα alternative splicing (Figure 2).  The simian virus 40 (SV40) late mRNA share a 
strong poly(A) site (SVL) and its sequence is used to represent the effect of  strong 
polyadenylation.  
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A series of constructs have been made with SVL poly (A) site introduced to either TRα1 
or TRα2 poly(A) site as a 175 nt, BamHI fragment. RNase protection assays (RPAs) and 
realtime PCR were used to study TRα1 and TRα2 expression level. These studies showed 
that SVL poly (A) signal substituted in TRα1 exon will aggressively compete with 
normal TRα2 splicing and result in almost exclusive production of TRα1. When the 
downstream TRα2 poly(A) site was replaced with the strong SV40 signal, the balance 
between TRα1 and TRα2 mRNA expression was also altered, resulting in increasing 
amounts of TRα2 splicing [S. Munroe and A. Schnell unpublished]. Unlike the exclusive 
TRα1 production result from TRα1 poly (A) substitution, the downstream SV40 signal 
will enhance TRα2 splicing but will not compete out TRα1 mRNA splicing. It appears 
that both upstream and downstream poly (A) sites are critical for maintaining TRα1/ 
TRα2 ratio. Introduction of a stronger TRα2 5’ splice site with a single nucleotide 
substitution (+5C/G) counteracts the effect of strong poly (A) signal of TRα1 and restore 
the normal balance.  Therefore, the strength of splice and polyadenylation sites also 
affects the balance between splicing and polyadenylation. Since both cis-acting splicing 
regulatory elements and polyadenylation are important for TRα alternative splicing it is 
important to study the interactions between polyadenylation and ESX10 and investigate 
their effects on the balance between TRα1 and TRα2. Using TRα system as model, we 
hope to explore the underlying regulatory mechanism of alternative processing and 
increase our understanding of the complexity of gene expression. 
 
B. Specific aims 
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As stated in the above introduction, the major goal of my study is to further identify and 
investigate cis-acting elements in alternative splicing of α-thyroid hormone (T3) 
receptor gene. Since polyadenylation also affects this process, the effect of strong 
poly(A) signal on TRα alternative splicing has also been studied. The specific aims of 
my study are:  
 
1. To characterize three ESE motifs within R100 region of ESX10 and further study 
the functional roles of ESX10 subfragments. These studies on ESE motifs are 
carried out by substituting ESE motifs in exon 10 with corresponding homologous 
sequence copied from the antisense strand of the Rev-erbβ gene sequence. The 
enhancing effects of the chimeric fragments are tested by in vitro studies with Dsx 
system. In vitro competition experiments are also used to characterize the functional 
role of ESE motifs in TRα2 alternative splicing. To further study the requirements 
for ESX10 activity, substitution of either half of ESX10 (GR) has been examined in 
transfection experiments using a truncated TRα minigene plasmid.  
 
2. To investigate the effect of polyadenylation sites in regulating TRα alternative 
splicing. Previous work indicates that inactivation of ESX10 blocks the normal 
TRα2 splicing. This effect of substituting a strong poly(A) site at 3’ end of TRα2 
will be studied with respect to the activation of cryptic splicing within G100 and 
R100 segments. Interestingly, the same strong poly(A) site enhances TRα2 splicing 
fidelity by simultaneously reducing TRα3 expression, a shorter variant of TRα2 
with a 3’ss within G100 
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Chapter II. Characterization of Bioinformatically Defined ESE Motifs  
                                   within ESX10 Enhancer  
A. Introduction  
In the Introduction we described the identification of ESX10 and the analysis of its 
enhancing capability through in vitro splicing. In order to analyze comprehensively the 
presence of typical ESE motifs within ESX10, we used bioinformatics approaches to 
study its sequence and provide insights for further studies. Through bioinformatics 
sequence analysis with Rescue-ESE program [43], three possible ESE motifs were 
identified within the R100 fragment of ESX10.  To further analyze their functional roles, 
a series of in vitro experiments are used to study these ESE motifs.  In this section I 
describe the results from the bioinformatics studies, following in vitro splicing and 
competition experiments to characterize the role of these ESE motifs in ESX10's 
enhancing effect. 
 
B. Further study of possible ESE motifs within R70 fragment  
Since many ESE elements are 6-7 nucleotides segment that are sufficient for binding 
specific SR proteins, several well-known programs including Rescue-ESE and FAS-ESS, 
ESE-finder and Splicing rainbow are applied to analyze the ESX10 sequence and predict 
possible ESE motifs. [43, 45, 46, 47]. By analyzing R100 sequence with Rescue-ESE 
program [43], three heptamers have been identified and further analyzed. Although even 
more clusters of Rescue hexamers are detected besides R100 in exon 10 (Figure 4), these 
hexamers in R100 are intriguing since they overlap five of six previously tested 42nt  
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TRα2 3’ss BsrGI
EcoRI
PflMI
G100
Figure 4.Sequence information about ESE motifs on exon10. 
ESX10 Sequence analysis with Rescue-ESE program. All predicted ESE hexamers within 
ESX10 have been marked above the sequence. The box circled out are selected possible 
ESE elements within R100 region. Each one of them is 7 nt long and comprised of two 
overlapping ESE hexamers. BsrGI and EcoRI sites define the end of GR fragment. EcoRI 
and the first PflMI site define the ends of the RM fragment.
G/R 
boundary
R100TRα3 3’ ss
Rev-erbα 3’ss
(antisense)
TRα2 stop
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subfragments (R42αB-R42αF)[36]. Each heptamer contains two overlapping predicted 
ESE hexamers and they are named Rescue1 (R1) Rescue 2(R2) and Rescue3 (R3) 
depending on positional difference (Figure 4). After predicting these ESE elements' 
position, various in vitro experiments are performed to directly test their effect on ESX10 
enhancing capability.   
 
1. Substitution of all three ESE motifs with Rev-erbβ sequence cause a sharp decrease of 
the enhancing capability of ESX10 subfragment. 
In order to determine whether these ESE segments are essential for ESX10’s activity, all 
three motifs were substituted with the corresponding Rev-erbβ sequence. In the Rev-erbβ 
sequence, R1 has 3 nucleotide substitution, R2 has 2 nt changed and R3 has 3 different 
nucleotide compared to the authentic TRα sequence (Figure 5E). Overall, eight 
nucleotide substitutions were introduced into R70αFαD’ (R123) and the modified 
fragment was inserted into truncated Dsx exons to test its enhancing capability. After 
adding chimeric fragment into Dsx system, the splicing activity (1.4%) dropped 
dramatically compared to addition of the original R70αFαD’ sequence (60%). Thus, the 
mutation of all three ESE motifs results a loss of 95% of the splicing activity (Fig 5A). 
These results suggest that the authentic sequences of these ESE heptamers are essential 
for maintaining the enhancing activity of ESX10 subfragments in vitro. 
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2. Substitution of single or double ESE motifs with Rev-erbβ sequence reduces 
enhancing capability of ESX10 subfragments in vitro.  
After observing that the substitution of all three ESE motifs caused a large decrease in 
R70 activity, we further studied the functional characteristics of each ESE element and 
the interactive relationships between them. Similar to the strategy used to investigate the  
effect of all three ESE heptamers, the substitution of each ESE motif was performed 
independently with corresponding Rev-erbβ sequence and the mutated R70 sequences 
were added to truncated Dsx exons to examine their effects (Figure 5B). The in vitro 
splicing results showed that after introducing mutation to single ESE motif, the 
enhancing activity of chimeric fragments decreased for every case. Among three ESE 
motifs, the substitution of three nucleotides in R1 induces the most significant negative 
effect on R70 enhancing capability, causing about 80% reduction on splicing activity 
compared to the intact R70 fragment (Figure 5C; splicing percentage: 11% in R1 
compared to 58% in αFαD’). Compared to the sharp drop in Dsx pre-mRNA splicing 
after R1 substitution, the substitution of either R2 or R3 individually had slight effect on 
splicing activity (Figure 5C: splicing percentage: 31% in R2 and 48% in R3 compared to 
58% in αFαD’).  From these results, we concluded that mutation of single ESE motifs 
could also attribute to the enhancing effect of ESX10 subfragments and R1 motif might 
be the critical for ESX10's overall enhancing function. 
 
The successful splicing inhibition after substitution R1 ESE motif raised another 
interesting question: is R1 the only contributor for ESX10's function or are the 
contributions of other ESE elements (such as the R2 and R3 motifs) also required to 
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achieve normal enhancing effect? To answer this question, we substituted every two out 
of three ESE motifs and tested their effects with similar methods to investigate the 
interaction between these elements (Figure 5B). The in vitro splicing results strongly 
suggested that the ESE motifs would interact with each other and work cooperatively. 
Mutation of R2 and R3 motifs alone only induced slight inhibitory effect on splicing 
activity compared to R123 fragment (Figure 5D; splicing percentage: 32% in R23 
compared to 65% in αFαD’ control; please see reference 36 for respective αFαD’ data). 
And their mutations combined with R1 (R12 and R13) were much more effective in 
inhibiting R70 enhancing activity (Figure 5D; splicing percentage: 8% in R12 and 7% in 
R13 compared to 65% in αFαD’ control; please see reference 36 for respective αFαD’ 
data). Compared to αFαD’ control, he inhibitory effects from the double mutations with 
R1 (R12 and R13) are slight lower than the substitution of all three motifs (R123) but 
higher than substituting R1 alone (R1) [36]. Considering the close positional distance and 
functional relationship between R2 and R3, it might be more reasonable to regard R2 and 
R3 as another functional element (R2/R3) for ESX10. These results confirmed the critical 
role for R1 heptamer on R70's enhancing capability and suggested that multiple 
enhancing elements within R100 might cooperate with each other to promote TRα2 
splicing.  
 
3. Functional analysis of the ESE motifs by competition experiments.  
Since many ESE motifs commonly bind members of the SR protein family, it was 
possible that the trans-acting proteins within nuclear extract would interact with these 
predicted ESE motifs. As a first step towards characterizing the involved protein factors, 
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in vitro competition experiments were performed. If the ESE elements binds to the 
protein factors present in nuclear extracts and these interactions are essential for the 
enhancing capability, an excess of normal R70 RNA fragment with original ESE 
sequence would competitively occupy necessary protein factors and inhibit the normal 
splicing of TRα2 competitively. In contrast, an excess of chimerical fragment with 
mutated ESE would not affect TRα2 splicing. In competition experiments, splicing 
reaction containing radio-labeled truncated TRα2 were incubated with different 
competitors RNAs (Figure 6A). The substrate pre-mRNA is transcribed from pα2 ∆BE 
construct which contains partial TRα exon9 and exon10. Originally, the RNA substrate is 
743 nt long and a final 430 nt product will be detected after intron removal from in vitro 
splicing. The competitor RNA fragments include wildtype sequence (competitor WT: a 
220 nt RNA fragment with wildtype ESX10 sequence), mutated sequence (competitor 
Mut: a 170 nt RNA fragment with ESX10 that has 3 ESE motifs substituted with Rev-
erbβ sequence) and corresponding Rev-erbβ sequence (competitor NS: a 220 nt RNA 
fragment with Non-specific Rev-erbβ sequence) (Figure 6B). Besides, all competitors 
have been applied to the pα2 ∆BE splicing with different concentrations.  According to 
the preliminary data, addition of 100nm competitor WT (original ESX10 sequence) 
results in a 20% decrease on the splicing activity (Figure 6C). This result reflects specific 
interaction between ESX10 and certain trans-acting factors present in the nuclear extract 
because the mutated competitor Mut only have a slight inhibitory effect on splicing. 
Comparatively, addition of the negative competitor NS (Rev-erb β sequence) didn’t 
induce obvious competition effect either.  These results suggest that the trans-acting  
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Figure 6. Inhibiting of TRα2 splicing with excess competitor RNA
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A:     The pα2 ∆BE pre-mRNA was incubated with 0, 50, or 100 nM of the labeled competitor 
WT(wildtype: ESX10 sequence), competitor NS (Non-specific Rev-erb β sequence) and 
competitor Mut(ESX10 sequence with mutated ESE motifs). All reactions were 
incubated for 90 minutes and the samples were collected at 0 min, 45 min, 90 min.
B:     The schematic structure of pα2 ∆BE pre-mRNA and competitor RNAs used in the 
experiments
C.     Percentage of Splicing for pα2 ∆BE in vitro splicing with different competitors. 
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factors in Hela nuclear extracts are required for ESX10 activity and the previous 
identified ESEs within this region might be critical in this cis-trans interaction. 
 
C. Discussion 
Regulation of alternative splicing involves the participation of various mechanisms and 
one major contributor is the existence of different cis-acting elements and following cis-
trans interactions. In this chapter, my studies focused on the further characterization of 
three ESE heptamers elements located within the 3’ half of ESX10. These ESE motifs 
were original identified through detailed sequence analysis of ESX10 with bioinformatics 
methods and their effects on the enhancing capability of ESX10’s subfragments are 
investigated by in vitro splicing. Afterwards, competition experiments are applied to 
further explore the possible cis-trans interaction within ESX10 region. My studies 
indicate that the mutation of eight nucleotides within these ESEs dramatically reduced the 
enhancer activity of ESX10 subfragments in vitro and also weakened the possible cis-
trans interaction.   
 
The studies related to Exonic splicing enhancer motifs 
In order to further study these ESE motifs within ESX10 region, the ESE sequences were 
investigated by replacing single or all ESE motifs with corresponding Rev-erbβ sequence 
and the enhancing capability of chimeric fragments are tested in vitro. Although my 
experiments indicate that the mutation of ESE heptamers induced significant negative 
effect on the enhancer activity of ESX10 subfragment, it is also possible that the effect is 
not from the elimination of original enhancer element but from the introduction of new 
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silencer. FAS-ESS, a bioinformatics program that can predict the existences of ESS were 
applied to test this hypothesis. After substituting three heptamers with Rev-erbβ sequence, 
a reduction on number of possible ESE motifs and increase of potential ESS candidates is 
predicted.  In order to further study whether the inhibitory effect is from the disturbance 
of original TRα2 sequence in heptamer motifs or from possible introduced ESS motifs, 
we used other sequences combination besides the Rev-erbβ substitution to test the 
enhancer activity of ESX10 subfragments. If other changes within these ESE regions 
could reduce the splicing activity, the uniqueness of these ESEs could be confirmed. 
Because R1 showed most significant effect among these three ESE motifs, we chose this 
ESE heptamer and changed its sequence by random scrambling the order of the 
nucleotides to disrupt the original ESE sequence (Generated with primers 774R and 
775R). These scrambled motifs were introduced into Dsx system and tested similar as 
other chimeric segments. Scrambled R1 sequence within the αR42F fragment showed 
reduced enhancing effect than the original TRα sequence (for example, 35% splicing 
αR42F compared to 23.2% splicing scrambled R1), although to a less extent than the 3nt 
Rev-erbβ substitution(1.4%). The results from scrambled experiments suggest that the 
authentic sequence of these ESE hepatmers might be critical for their enhancing effect 
and disruption of the nucleotides constitution would negatively affect their function. 
However, these in vitro splicing reactions showed high levels % input degradation(results 
not shown) so further work is required to quantify the induced negative effect of these 
substitutions.  
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Chapter III. Functional Analysis of ESX10 and  
its Subfragments (R100, G100)  
A. Introduction 
In Chapter II of this thesis, I described the positive effect of ESE elements located within 
R100 region of ESX10. My goal in this chapter is to further characterize the importance 
of ESX10 and its subfragments. Since both halves of ESX10 (G100 and R100) are highly 
conserved, constructs with specific substitutions were created and used to further analyze 
their effect on TRα2 splicing in vivo following transient transfection of HEK293 cells.  In 
this section, I describe the results from RNase Protection Assays(RPAs) and realtime 
PCR experiments to characterize the functional role of ESX10 and its subfragmnets. 
 
B. Study of ESX10, G100, R100 and the related cryptic splicing  
1. Analyzing the effect of ESX10 and its subfragments by RNase Protection Assay  
In order to investigate the functional importance of ESX10 and its subfragments on TRα2 
alternative splicing, a series of TRα minigene plasmids with mutated ESX10 were 
generated for expression in vivo.  After equally dividing ESX10 into two segments 
designated G100 and R100 according to their nearby restriction sites, plasmids that had 
substitution of each half of ESX10 with Rev-erbβ sequence were created for further 
studies: pErbAmβG100 (G100) and pErbAm-βR100 (R100). Another construct with the 
whole ESX10 substituted by corresponding antisense Rev-erbβ sequence was generated 
by Ms Schnell previously: pErbAm-βGR200 (GR200). After transfecting these three 
constructs and other plasmids (the vector pRC/CMV as a negative control and  
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A. The schematic structure of minigene plasmid we used in transfection. 293 HEK cells were tranfected and 
total RNA were collected and assayed afterwards. 
B. The probe used in the RPA overlaps 5’ss of TRα2, which indicate the expression of both TRα1 and TRα2 
spliced mRNA. The arrows indicate the corresponding bands of either product. The tested samples are 
different constructs with substituted ESX10 or its subfragments. The bottom panel is a high contrast 
version of the same RPA assay. The abbreviations used in RPA and realtime PCR calculations are: C-
Control Vector, WT- wildtype control (pCMVerbAα). G100- Substituting G100 of ESX10 with Rev-erb β
sequence (pErbAm Revβ G100). R100- Substituting R100 of ESX10 with Rev-erb b sequence (pErbAm
Revβ G100). GR200 - Substituting ESX10 with Rev-erb b sequence (pErbAm Revβ G100). 
C.      The bar graph on the  indicates the calculated TRα2 splicing percentage. The data used here were 
averaged from at least three independent assays. RNAs are from two independent transfections assayed 
in duplicate with different amount of input RNA. 
Figure 7. Analyzing the effect of ESX10 or its subfragments by RNase Protection Assay
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 pErbA as a wildtype control) into HEK293 cells, total RNA was extracted and used as 
substrate for RPA assays. RNAase Protection Assay was performed in order to compare 
the effect of the minigene constructs on TRα2 splicing.  The radio-labeled probe used in 
RPA overlapped the TRα2 5’ splice site sequence in exon 9A (Figure 7A). Since TRα1 
and TRα2 mRNA contain the shared exon9A sequence, the 5'ss probe will hybridize and 
protect both products. In the assay, two different RNA concentrations (5 ug and 2.5 ug) 
were used for each minigene and two independent experiments were performed. The 
relative splicing levels of both TRα1 and TRα2 were calculated from two separate 
experiments. The resulting data show that in the minigene without original ESX10 
sequence (GR200), the splicing of TRα2 reduced greatly (2.8% splicing) compared to 
wildtype control WT (20.5%) (Figure 7B and 7C). Substitution of either ESX10 
subfragment (G100 or R100) also caused reduction of TRα2 compared to the wildtype 
control (G100:9.0% and R100:11.5%), but their decreasing folds were lower than 
substitution of the full ESX10 sequence (GR200) (Figure 7B and 7C). These results 
suggest that ESX10 is functional important for TRα2 splicing in vivo and substitution of 
ESX10 and its subfragments with Rev-erbβ sequence will also reduce normal TRα2 
splicing.  
 
2. Analyzing the effect of ESX10 or its subfragments by realtime PCR assay  
Since the above RPAs would measure all splicing events at TRα2 5’ss, we use realtime 
PCR to confirm the specific inhibition of TRα2 splicing. With primers specific for TRα1 
and TRα2, realtime PCR assays were performed to further characterize the functional 
importance of ESX10 and its subfragments (Figure 8A). From realtime PCR results, we  
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A. The schematic structure of minigene plasmids we used for transfection. After collection of total RNA, 
Reverse-Transcription PCR were used to generate cDNAs as templates for realtime PCR. Various primer 
pairs were used to analyze the  expression level of TRα1 and TRα2. In the figure, A and B stand for 
primer set designed for different purposes. A- 936F, A1-937R, A2-1499b. B- 900F, B1-1467R, B2- 905R. 
The sequence of primers are included in Appendix- E.
B. The calculated splicing percentage of TRα2 based on Realtime PCR data with primer set A/A1 and B/B1. 
The data used were averaged from two independent Realtime reactions and each reaction had three 
parallel assays, using primers pairs  A/A1 for TRα1 and B/B1 for TRα2.  % splicing is calculated from the 
difference between CT  values for TRα1(A/A1) and TRα2(B/B1) realtime PCR as described in Methods 
(Chapter VI). These percentages assume negligible constrictions from alternatively spliced form 
including TRa3 and cryptic splicing within βGR200 sequence.
C. Selected samples were assayed with 2% Agarose gel to test their matched size. The templates and 
primer sets were indicated above the figure. The lower panel is a high contrast version of these bands.
CSS stands for products from cryptic splicing sites. 
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confirmed our findings that substitution of both subfragments showed decreasing TRα2 
splicing (Figure 8B). However, PCR analysis of minigene expression also revealed 
differences. Using the primer set B/B1 specific for TRα2 detection, all the minigene 
constructs expressed detectable levels of TRα2 mRNA as seen by electrophoretic analysis 
(Figure 8C). However, with primer set B/B2, multiple spliced products were observed 
and difference in expression patterns became apparent (Figure 8C). In the minigene with 
wildtype, a shorted product was evident, which matches the size of TRα3, a previous 
reported TRα isoform[13,14]. The subsequent sequencing of the additional product 
confirmed the existence of TRα3 in our system and further studies about TRα3 will be 
described in Chapter IV. With primer B/B2, G100 showed similar pattern as wildtype 
control (WT), where TRα2 and a band with similar size to TRα3 were detected. However, 
substitution of G100 with Rev-erbβ sequence eliminate key residues within the TRα3 
3’ss (CAG/C     TTT/A). After analyzing the sequence results of the respective bands, it 
is clear that the product with TRα3 size is not spliced from the authentic 3' TRα3 splice 
site but from a cryptic splice site in the substituted Rev-erbβ G100 sequence, which is 2nt 
downstream the position of authentic TRα3 splicing site (Table I). On the other hand, 
R100 showed a similar banding pattern as GR200, where a different product from cryptic 
splicing was predicted. The realtime PCR results indicate that both G100 and R100 have 
enhancing effect and substitution of each subfrgament would induce decrease on TRα2 
splicing. However, the electrophoretic analysis with primers B/B2 indicated that the 
substitution of R100 induced greater inhibitory effect on TRα2 splicing (in Figure 8C, 
G100 showed normal TRα2 band while R100 didn’t), which suggest that R100 is 
functionally more important than G100.     
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positi
on
sequence
Consensus N/A YYYYYYYYNYAG/GNN
TRα2 3'ss +1 CGTCTCGTAAAG/GAG
TRα3 3'ss +117 CATGTTGTTCAG/GGU
TRα2 3'ss CSS(R100) +194 TTCATTATTAAG/GUC
TRα3 3'ss CSS(G100) +119 TGTTGTTTAAAG/AUC
In this table, R stands for purine nucleotides, N for random nucleotides.  
3’ss and CSS respectively represents 3’ splicing site and cryptic splicing 
sites.
Table I. Sequence for 3’splice sites ofTRα2 and TRα3
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After isolating the additional products from R100, sequencing analysis confirmed the 
existence of cryptic splicing product and its splicing site (Table I). The cryptic splicing 
site located 197 nt downstream of TRα2 3’ss and 65 nt upstream of EcoRI site of GR 
fragment, which belonged to the R100 region of substituted ESX10. We also identified 
this cryptic splicing product in GR200 and more studies would be introduced in Chapter 
IV. 
 
Studying the expression level of cryptic splicing through realtime PCR 
Based on the data from RPA assays and realtime assays, we concluded that substitution 
of ESX10 with Rev-erbβ sequence (GR200) caused dramatically decreased TRα2 
splicing and substitution of either ESX10 subfragment (G100, R100) reduced TRα2 
splicing moderately compared to complete ESX10 substitution (Figure 9B). However, the 
substitution of antisense Rev-erbβ sequence in ESX10 also introduced a cryptic 
alternative 3’splice site. Therefore, the observation of cryptic splicing in G100, R100 and 
GR200 raises the question whether the absence of ESX10 negatively affects the overall 
splicing level or simply reduces TRα2 splicing accuracy? To answer the question, we 
used realtime PCR methods with different primer sets to measure the expression level of 
cryptic splicing.  
 
In the experiments, primer set A/A2 was used to estimate the total expression of TRα 
mRNAs. The percent splicing of TRα1, TRα2 and additional products are calculated 
based on the realtime threshold value (CT) from different primer sets: A/A1 for TRα1 and 
B/B1 for TRα2. B/B2 is designed to estimate the expression level of other splicing  
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Figure 9 Comparing the splicing level of different components among minigenes
A. The schematic structure of minigene plasmids we used for transfection. Various primer 
pairs were used to analyze the  expression level of TRα1 and TRα2. A- 936F, A1-937R, 
A2-1499b. B- 900F, B1-1467R, B2- 1495R, B2- 905R.(See Appendix- E for details)
B. Comparison of the calculated TRα2 splicing percentage between RNase Protection 
Assays and Realtime PCR. TRα2 splicing in different minigene construct was compared 
to the wildtype control(set as 100%). For RPA, The probe overlaps 5’ss of TRα2 was used 
to indicate the expression of both TRα1 and TRα2 spliced mRNA. For Realtime PCR 
assays, The calculated splicing percentage of TRα2 based on the data from primer set 
A/A1 and B/B1. See Figure 7C and 8B for details.
C. Comparison of the expression of TRα1, TRα2 and downstream spliced products(include 
cryptic splicing). The result was generated by calculating the corresponding percentage 
with CT values from primer set A/A1(TRα1) ,B/B1(TRα2) and B/B2(For DS: downstream 
splicing). CT values of A/A2 is set for the all the transcripts shared with exon8 and exon
9A. The %spliced represents the combined percentage of TRα1, TRα2 and downstream 
(DS) product with different minigenes. Results of 2 or 3 respective experiments are 
shown for each constructs.
D. Selected samples were assayed with 2% Agarose gel to test their matched size. The 
templates and primer sets were indicated in the figure. The lower panel is a high 
contrast version of these bands. Abbreviation for plasmids used in the Figure: C-control, 
WT-wildtype, SVLα2-SVLα2, G100-βG100αR100, R100-αG100βR100, GR200-βGR200, 
GR200+SVLα2-βGR200+SVLα2
 
 
 
 33
products downstream of TRα2 3’ss. Because this primer favors the smaller sized 
products, it can be used to estimate the relative expression level of TRα3 and cryptic 
splicing in comparing to selective constructs. Similar to conclusion from RPA and 
realtime PCR assays, the results suggested that after substitution of ESX10 with Rev-
erbβ sequence (GR200), the TRα2 splicing percentage reduced dramatically compared to 
wildtype control (TRα2- GR200:2.6% compared to WT:20.4%) and TRα1 splicing 
percentage increased correspondingly as well. (TRα1- GR200:96.3% compared to 
WT:74.7%) (Figure 9C). Substitution of ESX10 subfragments (G100, R100) moderately 
reduced TRα2 splicing (TRα2- G100:8% and R100:20.8%). With primer B/B2, splicing 
products from different splice sites were indicated after PCR amplification (Figure 9D, 
the panel with primer B/B2). The electrophoresis results indicated that in R100, GR200 
and GR200+SVLα2 minigenes, only cryptic spliced products was produced. Because in 
G100, normal spliced TRα2 is detected but in R100 we observe mainly cryptic splicing 
products, we suggested that R100 is more important for TRα2 splicing than G100. This 
statement also agrees with conclusions from previous in vitro experiments that R100 
fragment showed more enhancing capability than G100 [36].  
 
Although the substitution of ESX10 and its subfragments (R100) induced cryptic splicing, 
the expression of cryptic splicing (DS- downstream splicing) in R100 and GR200 is 
much lower compared to normal TRα2 splicing (DS splicing in R100: 0.1% and GR200-
0.1%; Compared to the TRα2 splicing in WT: 20.4%). These results suggest that ESX10 
and R100 are functional critical for normal TRα2 splicing and the overall splicing level 
was not reduced dramatically. Since the expression levels of introduced cryptic splicing 
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products are much lower than TRα2, this conclusion would not be biased by the 
appearance of cryptic splicing. Interestingly, the expression of downstream splicing after 
ESX10 substitution was promoted greatly by strong downstream poly(A) signal (DS-
GR200:0.1%; GR200+SVLα2:18.2%). In next chapter, the effect of this strong 
polyadenylation signal from the SV40 virus on splicing of TRα2 will be examined in 
more details.      
 
C. Discussion: 
In this chapter, the functional role of ESX10 and its subfragments (G100 and R100) have 
been studied through in vivo experiments. Constructs with substitution of ESX10 and 
both subfragments (G100 and R100) have been created and RNase Protection Assays and 
realtime PCR were used to evaluate the expression levels of normal spliced TRα2 and 
related cryptic splicing.  
 
Studies of ESX10 subfragments with RPA and realtime assays 
In order to study the functional effect of ESX10 subfragments, both RNase Protection 
Assay and realtime PCR assays were used to investigate TRα alternative splicing. In 
RNase Protection Assay, the substitution of intact ESX10 with Rev-erbβ sequence 
resulted a sharp decrease on TRα2 splicing (2.8%) compared to wildtype control 
WT(20.5%). Substitution of either ESX10 subfragment (G100 and R100) with antisense 
Rev-erbβ sequence causes reduction of TRα2 splicing (G100:9.0% and R100: 11.5%) 
(Figure 7B and 7C). Although both G100 and R100 reduced TRα2 splicing, these 
substitutions were substantially less effective than GR200. The realtime PCR data 
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showed similar results. Compared to wildtype control WT(16.5%),  GR200 resulted a 
sharp decrease(0.2%) and the respective TRα2 splicing percentage for G100 is 6.0% and 
R100 is 8.4%(Figure 8B).  However, realtime PCR data in Figure 8B measured only 
TRα2 splicing relative to TRα1 while the RPA results in Figure 7C measure all splicing 
of the 5'ss in exon 9A. Therefore, both methods suggested that ESX10 sequence is 
functionally important for TRα2 splicing and its subfragments(G100 and R100) also 
indicate certain level of enhancing capability and the substitution of either half induced a 
detectable drop on normal TRα2 splicing. The data also indicated that the G100 
substitution caused more decrease on TRα2 splicing than R100 substitution, which 
suggests that G100 might have more enhancing activity than R100 within the context of 
the ErbAm minigene. However, this conclusion doesn’t agree with previous in vitro 
results from our lab [36]. When R100 and G100 fragments tested in vitro, R100 enhanced 
dsx pre-mRNA to almost same level as GR200 and G100 was much less efficient. 
Another proof is that in R100, only cryptic splicing product can be detected with 
electrophoresis and in G100 we observed mainly normal TRα2 product. Therefore, we 
conclude that although substitution of G100 with Rev-erbβ sequence also causes 
reduction of TRα2 splicing, R100 is more critical for TRα2 splicing and its substitution 
will directly inhibit the normal TRα2 splicing. More work is required for studying the 
expression level of TRα2 in G100 (pErbAm-βG100) to further investigate the effect of 
G100 on TRα alternative splicing. 
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Validity of the R100 and G100 minigene constructs 
After introducing the substitution of ESX10 subfragments (in G100 and R100 constructs), 
we detect several nucleotide mutations outside of ESX10 as shown in Appendix A. 
Compared to rat TRα sequence, one adenine has been mutated into guanine at 160 nt 
downstream of EcoRI site (the 3’ end of ESX10) in G100 construct. In R100 construct, 
one cytosine has been changed into thymine 210 nt downstream of EcoRI site and one 
adenine has been changed to guanine in 271 nt downstream of EcoRI site. The 
appearances of several point mutations within the newly generated constructs are 
probably due to the error during recombinant PCR process. Although it is possible that 
the introduced nucleotide changes might induce unpredictable results, we assume that 
these few scattered mutations have trivial effect on TRα alternative splicing in these 
minigenes. 
 
Related studies concerning cryptic splicing  
As the name describes, cryptic splicing involves splicing at sites not normally used. 
Cryptic splice sites often resemble to normal splice sites but are not selected until a 
mutation is introduced that alters usage of authentic splice site. In this Chapter, we 
identify three cryptic splice sites downstream of TRα2 3' splice site. These include 3’ 
splice site for TRα3, a minor variant which was first describe more than 20 years ago [13] 
and two sites introduced by Rev-erbβ substitution. The introduced cryptic splicing site in 
G100 is very close to the TRα3 splicing site in original TRα sequence and therefore a 
product have similar size to TRα3 was observed.  In contrast, the R100 (pErbAm-βR100) 
shares a similar cryptic splicing site in substituted R100 with GR200 (pErbAm-β200). As 
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can be seen in Table I, these are all slightly poorer matches to the mammalian consensus 
sequence. Interestingly, the two sites in the Rev-erbβ sequence both resemble the normal 
TRα2 3'ss in that they have a AAG/G splice site sequence (Table I).  
 
In our system, although the introduced cryptic splicing is close to the authentic TRα2 
splicing site, the sequence for normal TRα2 3' splicing site has not been mutated.  This 
raises a challenging question related to the function of ESX10: does cryptic splicing 
occur because of the missing of correct ESX10 sequence or does introduction of cryptic 
splice sites compete with the normal splicing of TRα2?  For cryptic splicing within in 
GR200 and R100, the introduced cryptic splice site might not so strong as to compete 
efficiently with the authentic TRα2 3’ss. Rather the absence of the enhancer activity of 
ESX10 may change the splicing pathway for TRα2 5’ss. On the other hand, the cryptic 
splice site within the G100 substitution is very close to the original TRα3 splicing 
location. It is possible that (undefined) elements that direct splicing of TRα3 results in 
selection another usable site near the original site. Although the importance of cryptic 
splicing is trivial compared to the ESE studies, the selection between different sites 
(strong or weak) might provide reasonable explanation for the interaction between cis-
acting elements and normal splicing factors. 
 
The endogenous TRα2 in transfected HEK293 cells affect the realtime PCR results 
One problem we encountered in the realtime PCR process is in transfected HEK cell or 
cell transfected with vector as negative controls, we found a positive signal for TRα2 
splicing. Although the expression level is much lower compared to the experimental ones, 
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it would affect the measurement of minor splicing from analysis of realtime data. One 
hypothesis is that endogenous TRα2 spliced in human cells would also be detected and 
included in the CT values and low levels of TRα2 might represent cross contamination. In 
order to solve this problem, we isolated the TRα2 PCR product obtained from 
untransfected cells and compare the sequencing result from this sample with human and 
rat sequence. Since the exon10 of TRα2 is highly conserved between these two species, 
we used the nucleotides difference among exon 8 and exon 9 as major criteria for our 
judgments and overall five nucleotides were accepted during the process. The sequence 
results demonstrate the existence of endogenous TRα2 from human cell (Appendix-B). 
Therefore, the CT values from realtime PCR correctly represent the expression level of 
TRα2 and not adventitious contamination or some other artificial signal.  
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Chapter IV. Effect of strong polyadenylation on TRα2 alternative splicing 
 
A. Introduction 
Polyadenylation is an important post-transcriptional process for eukaryotic mRNAs. This 
chapter focuses on the contribution of polyadenylation to the regulation of TRα2 splicing.  
In our system, the sequence of simian virus 40 late (SVL40) mRNA is used as a strong 
polyadenylation signal, and the effect of this strong downstream poly(A) on TRα2 and 
TRα3 expression was studied. We also investigated TRα2 splicing with a strong 
downstream poly(A) signal when the ESX10 was substituted. Finally, the effect of strong 
poly(A) signal on TRα2 splicing was also studied when authentic TRα2 5’ss was 
disrupted.  
 
B. Analysis of TRα3 splicing demonstrates that downstream SVL poly(A) signal 
enhances the efficiency and fidelity of normal TRα2 splicing.  
When using pCMVerbAα minigene as a wildtype control, TRα3, a different isoform of 
TRα2 with a shorter size was detected by PCR (Figure 10B). Sequencing of the small 
PCR product seen here and Table I also indicated that this product represents TRα3 
3’spliced site, which is 117 nt downstream of the TRα2 3’ss (Figure 10A, Figure 4 and 
Table I). Next, a known strong poly(A) site, late SV40 was inserted in place of 
downstream TRα2 poly(A) site to test the effect of strong pA on TRα3 splicing. 
Surprisingly, in the construct that has strong TRα2 poly(A) signal, the expression of 
TRα3 was  reduced dramatically in comparison with the TRα2 mRNA (Fig 10B). 
Realtime PCR results with primer specific for TRα2 splicing also showed that the strong  
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TRα2
TRα3
WT     SVLα2
Fig 10. Introduction of strong poly(A) site SVLα2 increase TRα2 
splicing fidelity and eliminate TRα3 expression
A
C
B
A. Schematics structure of TRα2 and TRα3
B. Regular PCR results confirm an elimination of TRα3 expression and   
increase on TRα2  expression. A/A1 and B/B1 were used.
C. Real-time data indicate that TRα2 splicing increases with strong downstream 
polyadenylation. The results are from calculation of TRα2 percentage from a 
combination of TRα1 and TRα2. (See Chapter V for more details)
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poly(A) signal enhances the expression level of regular TRα2 splicing compared to TRα1 
splicing (Figure 10C). Thus it appears that inserting a strong poly (A) signal downstream 
of TRα2 increases the splicing fidelity of correct TRα2. Expression level of TRα3 
isoform would be inhibited and TRα2 splicing is enhanced.  
 
C. Effect of the Strong Poly(A) Signal on Cryptic Splicing  
1. The effect of downstream strong poly(A) signal on TRα2 splicing when normal TRα2 
5’ss is disrupted  
In an effort to determine  wether the strong poly (A) for TRα2 can compete directly with 
that for TRα1 in the absence of TRα2 splicing, transfection were carried with a minigene 
construct that lack the TRα2 5’splice site (pErbAm ∆5'ss) paired with downstream strong 
polyadenylation site of TRα2 (pErbAm ∆5'ss+SVLα2). It was expected that the major 
products would be two RNAs differing only in their choice of poly(A) sites.  In pErbAm 
∆5'ss, six nucleotides were changed compared to the TRα2 5’ss consensus sequence 
(Figure 11A) and previous results from our lab indicated that this mutation of TRα2 5’ss 
(∆5'ss) completely blocks TRα2 splicing [44]. Conventional PCR results suggested that 
disturbance of TRα2 5’ss also inhibited the expression level of TRα3(Figure 11B). TRα2 
splicing is not enhanced by the strong TRα2 poly (A) signal when authentic 5’ss was 
disturbed (pErbAm∆5'ss+SVLα2). However, cryptic splicing products were detected in 
pErbAm∆5'ss and promoted by the SVL poly (A) signal (pErbAm∆5'ss+SVLα2) (Figure 
11B). After sequencing the respective bands, two cryptic splice sites have been identified 
located 53 nt and 142 nt downstream of normal TRα2 5’ss in exon 9 (Fig 11A).  The 
more distal site (CSS2) did not yield a clear sequence suggesting that the large  
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Figure 11  Strong poly(A) site activates weak splice site near TRα2 5’ss 
TRα2 5’ss(exon 9A)
A. Sequence analysis of exon9 in TRα. Different splicing sites are marked: ss stands for 
splicing site, CSS1 and CSS2 represents cryptic splicing sites 1 and 2. Sequence 
substitutions in 5’ss of pErbAm△5’ss are shown above. 
B. Conventional PCR amplification after reverse transcription are used to check TRα2 
splicing. With constructs having mutated 5’ss for on exon 9, a decrease of TRα2 has been 
detected.  A strong poly (A) site will enhance the use of available weak splicing site and 
increase the expression of cryptic spliced products. The primer set used to check cryptic 
splicing is 936F/905R.
A
B
TRα2
TRα3
CCGAACTCTTCCCCCCACTCTTCCTGGAGGTCTTTGAGGATCAGGAAGTCTAAAGCCTCAGGCGGCCA
3’ss
CAG/ACCGCTCTGGCCTGCTGTGTGTGGACAAGATCGAGAAGAGTCAGGAGGCCTACCTGCTGGCGTT
TGAGCACTACGTCAACCACCGCAAACACAACATTCCGCACTTCTGGCCCAAGCTGCTGATGAAG/GTG
ACTGACCTCCGCATGATCGGGGCCTGCCACGCCAGCCGCTTCCTCCACAT/GAAAGTCGAGTGCCCCA
GAGG/GTGTGC
CSS1
CSS2
TRα1 stop
△5’ss: CC/CAC
AC GA
∆5'ss+SVLα2∆5'ssWTM
 
 43
PCR products may actually represent a mix of two (or more) products spliced a few 
nucleotides apart. It appears that a strong downstream poly (A) signal enhances the usage 
of weak splice site near the mutated TRα2 5’ss and increase cryptic splicing (Figure 11B).    
 
2. The effect of downstream strong polyA signal on TRα2 splicing in the absence of 
ESX10  
As we discussed in the Chapter III, normal TRα2 splicing was reduced greatly after 
ESX10 sequence substitution. Previous studies also showed that strong polyadenylation 
site could enhance TRα2 splicing activity (Figure 12A, Lanes WT and SVLα2). 
Therefore, a series of tests have been made to study whether a downstream strong poly 
(A) signal will also induce positive effects on TRα2 splicing in the absence of ESX10. By 
comparing the expression level of TRα1 and TRα2, we hope to investigate the 
interactions between ESX10 and polyadenylation mechanism.  
  
In order to study the effect of downstream strong poly (A) signal on TRα2 splicing in the 
absence of ESX10, a strong poly (A) has been introduced into the construct that has 
ESX10 substituted with corresponding Rev-erbβ sequence. Conventional PCR and 
realtime assays were used to analyze the expression level of TRα2 and other spliced 
product. The results from regular PCR indicated that normal TRα2 splicing was lost by 
substitution of Rev-erbβ sequence in ESX10 and the additional strong SVL40 poly (A) 
signal didn’t increase normal TRα2 splicing (Figure 12A).  The usage of introduced weak 
splicing sites near TRα2 3’ss were, however, enhanced after introducing downstream 
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A. Regular PCR bands indicate thatESX10 are critical for TRα2 correct splicing and 
strong poly(A) signals will enhance general splicing level and increase correct 
splicing with the existence of ESX10 enhancer. 
B.     The schematic structure of different splicing sites of wt and GR200  from 
sequence analysis and spliced product size.
Figure 12 Downstream polyadenylation activates cryptic splicing at TRα2 3'ss
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poly (A) site (Figure 12 B). The identity of the enhanced cryptic splicing products was 
confirmed by sequencing. 
 
D. Discussion: 
In this chapter, we further studied the relationship between downstream polyadenylation 
site strength and TRα2 alternative splicing. Previous results indicated that the 
downstream poly(A) will promotes the nearby splicing and my results indicate that the 
strong downstream poly (A) signal will not only enhance TRα2 splicing but increase the 
fidelity of TRα2 splicing by reducing TRα3 splicing. One possibility is that ESX10 
mediates the definition of exon 10, which may also explain why addition of the SVL site 
eliminates TRα3 splicing. However, insertion of the strong poly (A) signal also activates 
cryptic splicing at two sites near the 5’ss upstream in exon 9. In the absence of normal 
TRα2 5’ss, these cryptic spliced products are promoted with TRα2 downstream 
polyadenylation signal. With the antisense Rev-erbβ substitution for ESX10, the usage of 
introduced weakly cryptic splicing sites is enhanced by the strong SVLα2 replacement at 
TRα2 poly (A) site. Although the cryptic sites associated with ESX10 are only technical 
problems, it confuses our analysis on the ability of the Rev-erbβ substitutions to block 
normal TRα2 splicing. 
 
Previous experiments showed that disruption of TRα2 5’ss by the mutation (∆5'ss) would 
completely inhibit the TRα2 slicing. However, no cryptic splicing or TRα3 products 
were observed in a previous study using northern blot analysis, presumably because that 
technique is less sensitive than PCR [44]. In my experiments, the cryptic splicing was 
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detected during the process of studying the effect of TRα2 downstream poly(A) on TRα2 
splicing. With the primer A/B2, additional PCR products that are larger than those for 
TRα2 and TRα3 were detected. After sequencing, we concluded that elimination of the 
5'ss for TRα2 induces cryptic splicing at site 53 and 142 nucleotides downstream of the 
mutant site (Table II). And these cryptic splicing were weak in the ∆5'ss without SVLα2 
poly (A) site but their expression levels were greatly enhanced by TRα2 downstream 
poly (A) (Figure 11C).   The sequence for cryptic splicing site 1(CSS1) was proved 
consistent with reproducible experiments. However, the splicing site for CSS2 was not 
located consistently and several splicing sites were identified by separate sequencing data 
(CSS2 in Table II represent one confirmed CSS2 splicing sites). Therefore, we assume 
that there might be multiple cryptic splicing sites available near the identified CSS2 site 
and different products with similar size would be produced after disrupting correct TRα2 
5’ss.     
 
In this chapter, the presence of the cryptic sites associated with the strong SVL polyA site 
were identified and investigated by various approaches. Although previous studies 
indicate that the expression level of these cryptic splicing products is much lower than 
normal TRα splicing(Figure 9C), the existence of these cryptic splicing complicate 
analysis of possible interactions between the poly(A) site and the ESX10 splicing 
enhancer. Further work to eliminate the expression of cryptic splicing in our system 
would be helpful for characterization of the interaction between ESX10 and polyA and 
their effect on TRα alternative splicing. 
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position sequence
Consensus N/A AAG/GURAGU
TRα2 5'ss +1 AAG/GUGACU
TRα2 5'ss CSS1 +53 CAU/GAAAGU
TRα2 5'ss CSS2 +142 AGG/GUGUGC
In this table, R stands for purine nucleotides. 5’ss and CSS respectively 
represent  5’ splicing site and cryptic splicing sites.
Table II. Sequence of TRα2 5’ss and other cryptic splicing sites
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V. Discussion and Conclusion 
Advantage and limitation of mutation studies 
The characterization of ESX10 and its subfragments was investigated by mutation studies. 
These studies are normally carried out to further narrow down the key regulatory region 
in a defined large fragment.  If the authentic sequence contributes significantly to the 
enhancing effect of ESX10, mutation of the target sequence would cause an increase or 
decrease in the amount of splicing. However, if there is no effect after substitution, the 
region might not be as important as hypothesized. In our system, TRα minigene provides 
an good model to further study the regulatory elements, like enhancers within exon or 
intron [32, 34, 36, 37].  
 
The major limitation of this method is that mutations in vivo sometimes will activate 
cryptic splicing sites either within mutated region or near mutated authentic splicing site. 
In one study from Krainer and colleagues, the sequence difference between authentic 5' 
splice sites and cryptic splice sites has been investigated [48]. Different statistical scoring 
methods were used to compare the strength of authentic 5’ splice sites and cryptic 
splicing sites. The authentic 5’ splice sites ranked highest among all the accepted 
methods and the mutant sites ranked lowest. The cryptic splice sites received 
intermediate score compared to the authentic 5’ss and mutant 5’ss.  Interestingly, the 
activated cryptic splicing sites were not necessarily the best scoring alternative sites near 
the authentic 5’ splicing sites, which suggests that other factors could also contribute to 
cryptic splicing sites selection. For example, relative usage of cryptic splicing sites near 
normal 5’ss would be affected by increasing SR protein or hnRNP A/B in mutant 
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substrates of Hbb(human β-globin gene) [49, 50]. In our system, the cryptic splicing 
activated after disrupted TRα2 5’ss could be due to the loss of authentic splicing site. 
And the cryptic splicing happened within substituted ESX10 or its subfrgaments (G100 
and R100) might be due to the dysfunction of ESX10 and existence of other factors 
involved in alternative splicing. Further efforts on identifying the trans-acting factors 
would be necessary to characterize the mechanisms involved with ESX10 and its 
subfragments. 
 
The advantages and disadvantages of in vivo and in vitro methods 
In this thesis, I applied both in vivo and in vitro methods to investigate the identification 
and characterization of cis-acting elements for TRα2 splicing. The major advantages of 
Dsx in vitro splicing system are its sensitivity and quick application. Since this splicing 
system lacks its original enhancer and relies totally on the introduced enhancing segments, 
even an enhancer with low level could be investigated and slight change on the enhancing 
capability could also be easily detected. In R100, three ESE candidates have been 
predicted by Rescue-ESE program and their activities were tested through in vitro 
experiments (Figure 5). After testing, the R1 ESE motif seems to be the most efficient 
one among these three motifs and we can conclude that one important factor that could 
contribute significantly for the ESX10 activity and following TRα2 splicing. However, in 
the following in vitro competition experiments, the fragment with substituted R1, R2 and 
R3 did not compete against the pre-mRNA splicing as efficiently as authentic GR170 
fragments (Figure 6C). This suggests that the mutated fragments don’t bind some factors 
essential for TRα2 splicing. Combining the in vitro and in vivo results, we cannot 
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determine whether the segments overlapping R1 R2 R3 are necessarily the only ones 
required for TRα2 splicing. Further work would include narrowing the competitor 
fragments(from current GR170 to R70) and detecting trans acting factors. 
 
Although in vitro experiments are very sensitive for detecting possible enhancer elements, 
there are also disadvantages: in the in vitro system, the effect of certain factors inside the 
cell might be neglected and their absence or perturbation may affect the enhancing 
capability in real situation and biased the accuracy of our conclusion. Therefore, in vitro 
splicing test is useful approach for analyzing the activity of enhancers and in vivo studies 
would be helpful to confirm the results convincingly. Thus we further characterize the 
functional importance of ESX10 subfragments with a series of in vivo studies after 
creating constructs with substitution of either G100 or R100.  The results from RNase 
Protection Assay and realtime PCR suggested that both ESX10 subfragments had 
enhancing capability on TRα2 splicing and substitution of either G100 or R100 would 
caused the decrease on TRα2 splicing (Figure 7 and 8). On the other hand, the 
substitution of G100 reduced TRα2 splicing more effectively that the R100 substitution, 
which suggests that factors associated with G100 may also contribute significantly to 
TRα alternative splicing. However, previous in vitro experiments confirmed that R100 
had more enhancing capability than G100, which against the conclusion we draw through 
RPA and realtime assays.  
 
The contradictions between the enhancing capability of ESX10 subfragments in in vitro 
and in vivo experiments may be due to several reasons. First, when we test the activity of 
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G100 and R100 through in vitro experiments, the enhancing capability cis-acting 
elements and trans-acting factors on the boundary of the subfragments (upstream 
sequence of G100, boundary between G100 and R100, downstream sequence of R100) 
would be affected and their original function might be significant. Second, although the 
dsx in vitro experiments are sensitive approach for detecting enhancers, minor difference 
between in vitro and in vivo experiment (ie. the in vitro incubation environment and in 
vivo cell growing) could induce unexpected effect on the final results. Therefore, further 
efforts on identifying what proteins bind to ESX10 is necessary to better understand the 
mechanism and solve the problem.  Combining the results from both in vivo and in vitro, 
we further characterize the functional role of ESX10 subfragments and increased our 
understanding on the regulatory mechanism of ESX10.  
 
Studies related to Polyadenylation and cis-acting elements 
Generally, cis-acting elements normally work as the docking sites or targets for trans-
acting factors and affect the activity of the nearby splice sites [51, 52, 53]. 
Polyadenylation has also been confirmed to affect splicing through protein-protein 
interactions among polyadenylation factors and splicing factors, where downstream 
polyadenylation positively affect the activity of proximal splice site [54]. Splicing and 
polyadenylation factors also interact with RNA polymerase II and other interactions 
before transcription and processing are also likely to occur. Therefore, the next goal was 
to investigate the possible interactions between cis-acting elements and downstream poly 
(A) signals.  
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Recent studies also pointed to important interactions between chromatin structure and 
alternative splicing. For example, studies of the fibroblast growth factor receptor2 
(FGFR2) gene illustrate a possible relationship between histone modification and 
alternative splicing may provide insight into our results [55]. In this study, distinctive 
histone modifications were shown to correlate with the effects of cis-acting elements on 
the splicing outcome in a series of human genes. The recruitment of the splicing 
regulatory protein PTB that binds to RNA would be affected by a chromatin-binding 
protein MRG15.  Thus alternative spicing events may be regulated through this adapter 
system. Given these results, it is quite possible that polyadenylation factors also directly 
or indirectly interact with similar components of chromatin.  If such interactions can be 
confirmed, the bridge between cis-trans interaction mechanism and polyadenylation 
mechanism could be established.  
 
Conclusions and Summary 
In this thesis, we explored the role of ESX10 and the downstream poly (A) on promoting 
or facilitating TRα2 splicing. Three possible ESE motifs within ESX10 were identified 
and their enhancing effects on TRα2 splicing were investigated in vitro. Following in 
vivo approaches were applied to further characterize the functional importance of ESX10 
subfragments. In the end, we studied the effect of strong downstream poly (A) on TRα2 
splicing and other related splicing events (TRα3 and cryptic splicing). The results from 
these experiments suggest that the existence of cross-exon interactions involve three 
elements: the 3'ss, the ESEs (ESX10) and the pA site. This network of interactions may 
be targeted or affected by antisense RNA produced through transcription of the opposite 
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strand (Rev-erbα) indirectly, by altering the modification of the chromatin.  The roles of 
TRα1 and Rev-erbα as two regulatory proteins important for developmental regulation, 
differentiation and metabolic control suggest that expression of this locus may be 
regulated in many different ways.  TRα2 might function as an additional layer of 
regulation that modulates expression of these genes.  The physiological role of TRα2 is 
also itself remarkably elusive.  More than 20 years after its discovery the function of this 
protein is unknown despite the fact it is highly conserved and its expression is 
differentially regulated in different cells and tissues of eutherian mammals. This study 
may help to expand our current knowledge on regulatory mechanism of TRα alternative 
splicing and the possible interaction between TRα2 and other thyroid hormone receptor 
proteins. 
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VI. Materials and Methods 
 
Plasmids 
Constructs with ESX10 Subfragments Substitution 
To further investigate the functional effect of subfragments of ESX10, substitution of 
either halves of ESX10 was introduced into minigene constructs. The parent vector used 
was 633(pErbAm delta 2+SVLα2), which has a 200nt truncation downstream of EcoRI 
site on exon10. The mutated G100 (βG100αR100) and R100 (αG100βR100) insertion 
fragments were created by recombinant PCR.  For G100, primer 979F and 1493R were 
used to create upstream βG100 fragment and 982R and 1492F were used for downstream 
αR100 fragment. The recombinant βG100αR100 fragment was generated with 979F and 
982R. For R100 construct, Primer 979F and 1491R were used to create upstream αG100 
fragment and 982R and 1490F was used to generate downstream βR100 fragment. 
Similarly, the recombinant αG100βR100 fragment was generated with 979F and 982R as 
well. Both parent vector and the insertion fragments were digested with BsrGI and SbfI 
restriction enzymes and ligated by T4 DNA Ligase after digestion. Since the insertion 
introduced a 200 nt longer fragment into the parent vector, the mutations were confirmed 
by Bsu36I restriction enzyme digestion and sequencing results. During the sequencing 
process of the new constructs, several point mutations have been identified downstream 
of ESX10 (Appendix C). Although we didn’t detect any obvious cis-acting elements near 
the region where these mutated nucleotides were identified, these changes might 
introduce unpredicted effect on the potential regulatory mechanisms near these regions.  
Other used plasmid can be found in Appendix-D.   
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Cell lines: HEK293 cells (also referred as Human Embryonic Kidney 293), is derived 
from tissue culture of human embryonic kidney cells and stored in our lab.  
 
Transfection and RNA isolation 
The calcium phosphate mediated transfection was set up according to the standard 
procedure of Sambrook et al (1989). HEK293 cells were plated as concentration of 
2×10^6 per P100 plate 24 hours before transfection and 48 hours before RNA extraction. 
After one day, 5 ug of plasmid DNA calcium phosphate were transfected into each plate. 
The cells were rinsed 24 hours after transfection and fresh media was introduced. The 
RNA extraction was performed with RNA extraction buffer and 2x PK buffer. DNaseI 
and PK were used in the process to purify and concentrate the target RNAs. RNA 
extraction from part of the transfection undergoes Trizol prep extraction (TRIzol 
Isolation of RNA, DNA and Protein, Invitrogen). 
 
RNase Protection Assay 
To obtain the TRα1/TRα2 mRNA alternative splicing ratio, specific probes were 
designed according to the corresponding sequence. The DNA used to produce the radio-
labeled probes was generated by PCR with designed primers. Different probes were 
generated according to different spliced product and cryptic splicing. Various 
concentrations of RNA and probes were hybridized overnight. RNase Cocktail containing 
RNases A and T1 and following Proteinase K treatment were used to stop the reaction. 
The samples were extracted, ethanol precipitation, resuspended in FSB and load on a 5.5% 
polyacrylamide-urea gel. 
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In vitro transcription and splicing 
Most RNA substrates were generated with PCR templates. Different types of polymerase 
(T7 or SP6) were used according to promoter specificity. After Mix and incubate at 37 ºC 
for 60 minutes. DNase I was used to eliminate the residual DNA templates. After 
overnight EtOH precipitation, RNA pellets will be resuspended in 20 ul FSB and load on 
to polyacrylamide-urea gel to further isolate. Otherwise, equal volume of urea gel stop 
buffer can be added after in vitro transcription reaction and the mixture will be loaded 
onto a polyacrylamide gel. After treatment with elution buffer for 4 hours, phenol 
extraction and following precipitation are used to purify the RNA. For in vitro splicing 
reaction, nuclear extract was incubated with pre-mRNAs, and a certain portion of 
reaction was taken out after a fixed time period and incubates with PK for 25min. After 
precipitation, labeled RNA was resuspended in FSB and load to 5.5% gel.  
 
Quantitation of assays 
The dried gel after RPA and in vitro splicing were analyzed by scanning with Storm 
phosphor-imager to collect counts of each detectable band. Because the amount of 
unlabeled UTP and labeled hot UTP were preset before the reaction, the different number 
Us in different product are used to measure the actual percentage of spliced mRNA 
against unspliced product. 
 
Quantitation of mRNA expression level from realtime PCR 
After converting mRNA into complementary DNA with reverse transcriptase, we use 
realtime PCR to investigate the expression level of mRNAs. Since DNA amount doubles 
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after every cycle of PCR until it reaches the corresponding thresholds, the Ct values can 
be used to calculate the percentage of each product(TRα1, TRα2 or cryptic splicing 
product).  . And the difference between TRα1 and TRα2 Ct values was used to measure 
TRα1/ TRα2 ratio.  The lower Ct value is, the higher the initial mRNA presents in the 
reaction. And the specific calculation shows below:  
In Figure 8B, we use primer set A/A1 for TRα1 and B/B1 for TRα2 detection 
                              %TRα2 splicing = 100*TRα2/( TRα1+ TRα2) = R*100/(R+1) 
                              [R= TRα1/ TRα2 = 2Ct(B/B1)− Ct(A/A1)] 
In Figure 9B, we use primer set A/A1 for TRα1, B/B1 for TRα2, B/B2 for CSS and 
A/A2 to detect the expression of all the transcripts with shared exon8 and exon 9A. 
                              %( TRα1+ TRα2+CSS) = 100* (TRα1+ TRα2+CSS)/(all transcripts) 
                              [TRα1/ (all transcripts) = 2Ct(A/A2)− Ct(A/A1)] 
                              [TRα2/ (all transcripts) = 2Ct(A/A2)− Ct(B/B1)] 
                              [CSS/ (all transcripts) = 2Ct(A/A2)− Ct(B/B2)] 
In Figure 9C, the expression level of TRα1 and TRα2 were calculated. 
                             %TRα1 = 100*TRα1/( TRα1+ TRα2+CSS)  
                             %TRα2 = 100*TRα2/( TRα1+ TRα2+CSS)  
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Appendix-C 
 
Plasmid name Catalog # Description and application Vector  Application Source 
pHB∆6 9
β globin sequcne; negative control for in vitro splicing and competition 
tests pSP6 in vitro splicing SHM 
pBS500 101
β globin sequcne; negative control for in vitro splicing and competition 
tests pGem4 in vitro splicing SHM 
pRC/CMV 210 negative control for transfection and ESX10 study  pCMV transfection, PCR SHM 
pCMVerbAα 220 wildtype construct for transfection and ESX10 study pCMV transfection, PCR LV 
pCMVB324/5'ss 352 disrupted 5'ss of TRa2 and for poly(A) study pCMV transfection, PCR SHM 
pα2 ∆BD 493 TRa2 exon8-10; in vitro splicing and competition tests pGem3 in vitro splicing SHM 
pα2 ∆BE 494 TRa2 exon8-10; in vitro splicing and competition tests pGem3 in vitro splicing SHM 
pα2SE80∆BD 505 TRa2 exon8-10 and SEa2 included; in vitro splicing and competition tests pGem3 in vitro splicing SHM 
pErbA2 ∆BE 555 ∆BE fragment inserted; vector for constructs making pGem3 in vitro splicing VS 
pErbA2 ∆BE SE60 556 ∆BE fragment inserted and SE60;in vitro splicing and competition tests pGem3 in vitro splicing SHM 
pDSX100XK 585 exon10 sequnece included; for in vitro transcription pDsx in vitro splicing SHM 
pCMV324 α2 pA SVL 613 substitued poly(A) downstream; for poly(A) study pCMV transfection, PCR AS 
pErbAM∆5'ss SVLα2 625
disrupted 5'ss of TRa2 with substituted poly(A) downstream; for poly(A) 
study pCMV transfection, PCR SHM 
pErbAm ∆RM 632 200nt downstream of EcoRI site of exon10 truncated; for poly(A) study pCMV transfection, PCR SHM 
pErbAm SVLα2 633
200nt downstream of EcoRI site of exon10 truncated + donwstream 
poly(A) signal; for poly(A) study pCMV transfection, PCR AS 
pErbAm Revβ 200 635 ESX10 replaced by β sequemce; for ESX10 study pCMV transfection, PCR AS 
pErbAm Revβ 200 
SVLα2 636
ESX10 replaced by β sequemce and introduced poly(A) downstream; for 
ESX10 study pCMV transfection, PCR AS 
pErbAm Revβ G100 647
G100 replaced by β sequemce and introduced poly(A) downstream; for 
ESX10 study pCMV transfection, PCR CZ 
pErbAm Revβ R100 648
R100 replaced by β sequemce and introduced poly(A) downstream; for 
ESX10 study pCMV transfection, PCR CZ 
 
 
 67
Appendix-D 
Primers for in vitro studies 
 
Number Description of plasmid construct Direction Sequence (5' to 3') 
701L pDsx (upstream primer) F CGGCCAGTGAATTGTAATACG 
705L Dsx/KX-R42αD R
CTAGA GCTCTTCGGG CTCTGGTGCT GAAGAACCGG CCCTCGGAGA CT 
TACCGCGATCCAAGCTTATC 
706L Dsx/KX-R42αE R 
CTAGA GGTGCT GAAGAACCGG CCCTCGGAGA CTTCCCGCTT CACCAA 
TACCGCGATCCAAGCTTATC 
707L Dsx/KX-R42αF R 
CTAGA GG CCCTCGGAGA CTTCCCGCTT CACCAAACTG CTGCTCAAGC 
TACCGCGATCCAAGCTTATC 
711L Dsx/KX-R42βD R 
CTAGA GCACTAAGGA CCTTAATAAT GAAAAACCAT CCAAATGAGG CC 
TACCGCGATCCAAGCTTATC 
713L Dsx/KX-R42βF R 
CTAGA AT CCAAATGAGG CCTCTATTTT TACAAAACTG CTTCTAAAGT 
TACCGCGATCCAAGCTTATC 
723L Dsx/KX-R70αFαD' R CTAGAGCTCTTCGGGCTCTGGTGCTG 
724L Dsx/KX-R70αFβD' R CTAGA GCA CTA AGG ACC TTA ATA ATG AAA AAC CGG CCC TCG GAG ACT TCC CG 
725L Dsx/KX-R70βFαD' R CTAGA GCT CTT CGG GCT CTG GTG CTG AAG AAC CAT CCA AAT GAG GCC TCT AT 
726L Dsx/KX-R70βFβD' R CTAGA GCA CTA AGG ACC TTA ATA ATG 
735L/R Dsx/KX-R42αFRescue1 R 
CTAGA  GGCCCTCGGAGACTTCCCttTTtACCAAACTGCTGCTCAAGC 
TACCGCGATCCAAGCTTATC 
 42aF(rescue1) F GCTTGAGCAGCAGTTTGGTaAAaaGGGAAGTCTCCGAGGGCC 
736L/R Dsx/KX-R42αDRescue2,3 R 
CTAGA  Gca Cta aGG GCT CTG GTG aTG Aaa AAC C   GG CCC TCG GAG ACT 
TACCGCGATCCAAGCTTATC 
 42aD(rescue2,3) F AGTCTCCGAGGGCC/GGTTtTTCAtCACCAGAGCCCttAGtGC 
   GCaCTaaGGGCTCTGGTGaTGAAaAACCGGCCCTCGGAGACT 
737L/R Dsx/KX-R70αFαD'Rescue1,2,3 R CTAGA   GCA CTA AGG ACC TTA ATA ATG AAA AAC C   GG CCC TCG GAG ACT TCCCt 
738L/R Dsx/KX-R42αE(RSCU1,2) R 
CTAGA GGTGaT GAAaAACCGG CCCTCGGAGA CTTCCCttTTtACCAA 
TACCGCGATCCAAGCTTATC 
720R   GCAGTTTTGTAAAAATAGAGGCCT 
 R70aFaD'  
GCT TGA GCA GCA GTT TGG TGA AGC GGG AAG TCT CCG AGG GCC /GGT TCT TCA GCA 
CCA GAG CCC GAA GAG C 
 R70bFbD’  
ACT TTA GAA GCA GTT TTG TAA AAA TAG AGG CCT CAT TTG GAT /GGT TTT TCA TTA TTA  
AGG TCC TTA GTG C 
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759R Rescue 1,2,3 rectified R CTA GA GCAC TAA GGG CTC TGG TGA TGA AAA ACC GGC CCT CGG AGA CTT CCC t - 3' 
760R Rescue1,3-rectified R CTAGA  GCACTAA GGGCTC TGG TGC TGA AGA ACC GGC CCT CGG AGA CTT CCC t - 3'  
761R R70 aFD(R3) R CTA GAG CAC TAA GGG CTC TGG TGC TGA AGA AC  
762R R70 aFD(R1) R CTA GAG CTC TTC GGG CTC TGG TGC TGA AGA ACC GGC CCT CGG AGA CTT CCC T  
763R R70 aFD(R2) R CTAGA  GCTCTTC GGGCTCT GGTGaTG AAaAACC GGCCCTC GGAGACT TC 
764R rescue 2,3 R CTAGA  GCaCTaa GGGCTCT GGTGaTG AAaAACC GGCCCTC GGAGACT TC 
765R rescue 1,2 R CTAGA  GCTCTTC GGGCTCT GGTGaTG AAaAACC GGCCCTC GGAGACT TCCCt 
766R R42xtD R 
CTAGA GCc CTT CGtt CcC T ca TcC TGA AGA Aca Gt Cca aac Gat A Cc 
TACCGCGATCCAAGCTTATC 
767R R42xtE R 
CTAGA ca TcC TGA AGA Aca Gt Cca aac Gat A Cc TC CCG CTT CAC CAA 
TACCGCGATCCAAGCTTATC 
768R R42xtF R
CTAGA  Gt Cca aac Gat ACc TC CCG CTT CAC CAA gCT GCT cCT gcg cC 
TACCGCGATCCAAGCTTATC 
769R R70xtFxtD' R CTAGA GCc CTT CGtt CcC T ca TcC TGA AGA Aca Gt Cca aac Gat A Cc  TCC CGC 
770R R70xtFaD' R CTAGA GC TCT TCG GGC TCT GG TGC TGA AGA ACC  Gt Cca aac GAt ACc TCC CGC  
771R R70aFxtD' R CTAGA GC cCT TCG ttCcC T ca TcC TGA AGA Aca GG CCC TC GGA GAC TTC  CCGCT 
773R Dsx/KX-R42αD (R2) R 
CTAGA  GCT CTT CGG GCT CTG GTG aTG AAa AAC C  GG CCC TCG GAG ACT 
TACCGCGATCCAAGCTTATC 
774R Dsx/KX-R42αF (ScR1) R CTAGA GG CCCTCGGAGA CTTCCC atccgtc CAAACTG CTGCTCAAGC TAC 
775R Dsx/KX-R42αF (ScR2) R CTAGA GG CCCTCGGAGA CTTCCC accctgt CAAACTG CTGCTCAAGC TAC 
780R 
FD'(R123) primer matched to 
R100 R 
CTAGA GCA CTAA GGG CTC T GG TGA TGA AAA ACC GGC CCT CGG AGA CTT CCC TCG 
GAG ACT TCC Ctt TTt ACC AAA CTG CTG CTC AAGC 
781R betaG70  R CTAGA GGA GCT CTT GGC CTT TAA AGT 
782R alphaG70 R CTAGA GAA GCT GCT GTC CTT CCG GGT  
783R betaG100  R CTAGA TGC CAG ATC TTC GAT CTT TAA 
784R alphaG100 R CTAGA TGC CGG ACC TGC GGA CCC TGA 
785R DsxKX R CTAGA TA CCG CGA TCC AAG CTT ATC 
786F aG fragment F TTC GAT TCT GTA CAA GGG GGC AG 
787F bG fragment F TTC GAT TCT GTA CAG TTA CCA TC 
788F Rescue overlap F CCC TTA GTG CCG AAG AGC CCG 
789R Rescue overlap R CTA GAG ACC TGC TCA ATG CC 
790R Rescue mutated R 
GCA CTA AGG GCT CTG GTG ATG AAA AAC CGG CCC TCG GAG ACT TCC CTC GGA GAC 
TTC CCT TTT TAC CAA ACT GCT GCC G 
791F recombinant F(paired with 790R) F TTT TCA TCA CCA GAG CCC TTA GTG CCC GCA GCA GCG 
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792F adding T7 promoter for GR F CGA AAT TAA TAC GAC TCA CTA TAG GGA GAT ACA AGG GGG CAG CGG CAG A 
793F adding T7 promoter for bGR F CGA AAT TAA TAC GAC TCA CTA TAG GGA GAT ACA GTT ACC ATC AGT TCA T 
794F 3'ss probe forward F CGA CCT CGA GGG CCC GGT ACC ATT CCA GAG GCT CAT CTT GGA AT 
795R T7 promoter for 3'ss probe R CGA AAT TAC GAC TCA CTA TAG GGA GAC CTC GTC AGA GGA AGA GGA G 
796F T7 promoter for alpha R70 F CGA AAT TAA TAC GAC TCA CTA TAG GGA GAA GCT TGA GCA GCA GTT TG 
797R Reverse for alpha R70 R GCT CTT CGG GCT CTG GTG CTG 
798F T7 promoter for beta R70 F CGA AAT TAA TAC GAC TCA CTA TAG GGA GAA CTT TAG AAG CAG TTT TGT A 
799R reverse for beta R70 R GCA CTA AGG ACC TTA ATA ATG 
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Primers for in vivo studies  
Number Description of plasmid construct Direction Sequence (5' to 3') 
905R TRa2 146bp R CCT CGT CAG AGG AAG AGG AG 
936F TRa1 skip x9A 291bp F CCT GGA TGA TAC GGA AGT GG 
937R TRa1 skip x9A 291bp R TCC TCA AAG ACC TCC AGG AA 
1467R rTRa2 135bp R TCG AAC TCT GCA CTT CTC TCT C 
1468R rTRa2 140bp R CAG AAT CGA ACT CTG CAG TTC T 
1469F rTRa2del5'ss 190bp F  TGC TGA TGA CCC ACA CAG AT 
1470F rTRa2 5'ss6TG192bp F GCT GCT GAT GAA GGT GAC G 
1471F TRa2 wt 5'ss 192bp F GCT GCT GAT GGT GAC TG 
1472F CSS1 51bp F CGC TTC CTC CAC ATG AGA 
1473F CSS2 48bp F GCG GCC AGA GGG AGA 
1474F cross TRa3 185bp F ATA CGG AAG TGG CTC TGC TG 
1475R cross TRa3 185bp R GAC CTG CGG ACC CTT CAT 
1476F cross TRa3 127bp F GCT GTG TGT GGA CAA GAT CG 
1477R cross TRa3 127bp R GAC CTG CGG ACC CCT CAT 
1478F  cross b200 css 129bp F GCT GTG TGT GGA CAA GAT CG 
1479R cross b200 css 129bp R CGT GCA CTA AGG ACC TTC ATC 
1480F b200 insert139bp F CAC AAC ATT CCG CAC TTC TG 
1481R b200 insert139bp R TGA GGA GCT CTT GGC CTT TA 
1482R b200 insert189bp R TCA CCC TTA AGG CCT TTG TT 
1483F TRa2 ZCSS-2 89bp F TTC CTG GAG GTC TTT GAG GAT 
1484R TRa2 ZCSS-2 89bp R CCC CCT TGT ACA GAA TCG AA 
1485F TRa2 ZCSS-2 89bp F CCC ACT CTT CCT GGA GGT CT 
1490F R100betaA F CCG GCA ACT TTA GAA GCA GTT TTG TA 
1491R G100a B R TAA AGT TGC CGG ACC TGC GGA CCC TG 
1492F R100a C F CTG GCA GCT TGA GCA GCA GTT TGG TG 
1493R G100betaD R TCA AGC TGC CAG ATC TTC GAT CTT TA 
900F Exon 9A F TGT GTG TGG ACA AGA TCG AG 
1494R Corrected R123 primer R AAA CTG CTG CTC AAG CTG CC 
1495R TRa3 in wt or betaG100 R TCA CCA AAC TGC TGC TCA A 
1496R TRa3 in betaR100 R TTT ACA AAA CTG CTT CTA AAG TTG C 
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1497R betaR100 or GR200 css R TTG CAG GAA ACT CTC ATT CG 
1498R betaR100 or GR200 css R AGG CTT TGC AGG AAA CTC TC 
1499aR TRa 9A w/936F 86bp R CGA TCT TGT CCA CAC ACA GC 
1499bR TRa 9A w/936F 137bp R GGT GGT TGA CGT AGT GCT CA 
 
 
 
Primers in realtime PCR analysis 
Code Number Description of plasmid construct Direction Sequence (5' to 3') 
A 936F TRa1 skip x9A 291bp F CCT GGA TGA TAC GGA AGT GG 
A1 937R TRa1 skip x9A 291bp R TCC TCA AAG ACC TCC AGG AA 
A2 1499bR TRa 9A w/936F 137bp R GGT GGT TGA CGT AGT GCT CA 
     
B 900F Exon 9A F TGT GTG TGG ACA AGA TCG AG 
B1 1467R rTRa2 135bp R TCG AAC TCT GCA CTT CTC TCT C 
B2 905R TRa2 146bp R CCT CGT CAG AGG AAG AGG AG 
B3 1495R TRa3 in wt or betaG100 R TCA CCA AAC TGC TGC TCA A 
     
 
